Bacteria are essential partners in human health. They help process food, produce biologically active compounds, interact with the immune system and support the integrity of the intestinal environment. But in the digestive tract, location matters almost as much as composition.

The colon is designed to contain a dense microbial ecosystem. The small intestine has a different job: it must digest food and absorb amino acids, sugars, fats, vitamins and minerals efficiently. It normally contains microorganisms, but in much smaller numbers and under tighter physiological control.

When an excessive number of microorganisms—or an abnormal microbial community—develops in the small intestine and begins causing symptoms, the result may be small intestinal bacterial overgrowth, commonly known as SIBO.

The popular description “good bacteria in the wrong place” is useful, but incomplete. SIBO does not always involve beneficial bacteria migrating from the colon, nor is it simply a numerical problem. Changes in microbial composition, intestinal movement, anatomy, digestive secretions and the host’s underlying health may all contribute.

Most importantly, SIBO is not merely a positive laboratory result. It is a clinical disorder that should be interpreted in the context of symptoms, risk factors and the limitations of available diagnostic tests. (PubMed)

What Is SIBO?

SIBO is generally defined as an excessive concentration or abnormal composition of microorganisms in the small intestine that is associated with gastrointestinal symptoms, nutritional consequences or both.

Historically, diagnosis was based on bacterial counts obtained from fluid aspirated from the small bowel. More recent definitions recognise that the problem may involve not only the total number of bacteria but also the types of organisms present and their metabolic activity.

This distinction matters because the small intestine is not sterile. A healthy person naturally has microorganisms in the upper digestive tract. The goal is therefore not to eliminate all bacteria from the small intestine, but to maintain an ecological balance compatible with normal digestion, motility and absorption.

The American Gastroenterological Association has emphasised that the definition of SIBO still lacks complete precision. Scientists do not yet have a universally accepted description of the normal small-intestinal microbiome, and existing diagnostic methods detect only part of a highly complex microbial ecosystem. (PubMed)

Why the Small Intestine Usually Contains Fewer Microorganisms

Several protective mechanisms normally prevent excessive microbial accumulation in the small intestine.

Gastric acid

Stomach acid destroys or inhibits many microorganisms swallowed with food and saliva. Markedly reduced acid production may therefore allow more bacteria to survive and enter the small intestine.

Observational research has linked proton pump inhibitor use with a moderately increased risk of SIBO, although the strength of this relationship depends on the population studied and the diagnostic method used. Proton pump inhibitors remain valuable medications when appropriately prescribed and should not be discontinued without medical advice.

Intestinal motility

The intestine does not simply wait for food to move through it. Between meals, coordinated waves of muscular activity known as the migrating motor complex, or MMC, help move residual food particles, secretions and microorganisms toward the colon.

When this “intestinal housekeeping” mechanism is impaired, microorganisms may remain in the small bowel long enough to multiply. Abnormal motility is therefore one of the most important biological pathways associated with bacterial overgrowth.

Digestive secretions

Bile, pancreatic secretions and intestinal fluids help create conditions that limit uncontrolled microbial growth. They also support normal digestion and help flush the small intestine.

The ileocecal valve

The ileocecal valve separates the end of the small intestine from the colon. It helps regulate the movement of intestinal contents and may reduce the backward migration of colonic material.

Intestinal immunity and the mucosal barrier

Secretory immunoglobulins, antimicrobial peptides and the intestinal lining help regulate which microorganisms can survive close to the mucosa.

SIBO can develop when one or more of these protective systems becomes impaired.

What Happens When Microorganisms Multiply Too Early?

Most dietary carbohydrates, proteins and fats should be digested and absorbed before they reach the colon. When too many microorganisms are present in the small intestine, microbial fermentation may begin prematurely.

This can produce several effects.

Excess gas production

Microorganisms can ferment carbohydrates into hydrogen, carbon dioxide, methane and other metabolites. Gas production may contribute to bloating, pressure, abdominal distension, belching and flatulence.

However, the amount of gas measured does not always correspond directly to symptom severity. Intestinal sensitivity, abdominal wall responses, transit time and the brain–gut axis can influence how strongly a person experiences distension.

Osmotic effects and diarrhoea

Microbial metabolism may interfere with carbohydrate absorption. Unabsorbed molecules can retain water in the intestinal lumen, contributing to loose stools or diarrhoea.

Disruption of fat digestion

Some bacteria can modify or deconjugate bile acids. When bile acids become less effective, fat digestion and absorption may be impaired. In more severe cases, this can contribute to fatty stools, weight loss and deficiencies of fat-soluble vitamins.

Competition for nutrients

Microorganisms may consume certain nutrients before the body can absorb them. Vitamin B12 deficiency is a recognised possible consequence of severe or prolonged bacterial overgrowth, although it is not present in every patient.

Folate levels may sometimes be elevated because certain intestinal microorganisms can produce folate.

Changes in the intestinal environment

Microbial metabolites may interact with the intestinal lining, immune system and enteric nervous system. The clinical importance of these changes varies, and many proposed mechanisms still require stronger human evidence.

Readers interested in the wider relationship between microbial imbalance and intestinal integrity can also explore how the gut barrier, bowel regularity and the body’s natural elimination processes are interconnected.

The Most Common Symptoms of SIBO

Symptoms commonly associated with SIBO include:

• bloating or visible abdominal distension,
• excessive intestinal gas,
• abdominal discomfort or pain,
• diarrhoea,
• loose or irregular stools,
• nausea,
• a feeling of fullness after eating,
• and, in some people, constipation.

More advanced cases may involve:

• fat malabsorption,
• unintentional weight loss,
• vitamin or mineral deficiencies,
• anaemia,
• weakness,
• or signs of malnutrition.

These symptoms are not specific to SIBO. Similar complaints can occur in irritable bowel syndrome, coeliac disease, lactose or fructose malabsorption, inflammatory bowel disease, pancreatic insufficiency, bile acid diarrhoea, constipation, pelvic floor dysfunction and several other conditions.

For this reason, symptoms alone cannot reliably confirm bacterial overgrowth. The AGA identifies bloating, diarrhoea and abdominal pain or discomfort as the symptoms most traditionally associated with SIBO, while emphasising the uncertainty surrounding its definition and diagnosis.

Who Is More Likely to Develop SIBO?

SIBO should not be viewed as a single disease with one cause. It is often a secondary consequence of another condition that alters intestinal anatomy, motility or digestive defences.

Structural changes

Conditions that create areas of intestinal stagnation can allow microorganisms to accumulate. Examples include:

• surgically created blind loops,
• certain forms of gastric or intestinal surgery,
• small-bowel diverticula,
• strictures or partial obstructions,
• adhesions,
• fistulas,
• and altered connections between sections of the intestine.

Motility disorders

Reduced intestinal movement may occur in people with:

• systemic sclerosis,
• diabetic autonomic neuropathy,
• chronic intestinal pseudo-obstruction,
• certain neurological or muscular disorders,
• or medication-related slowing of intestinal transit.

Opioid medications are particularly relevant because they can markedly reduce gastrointestinal motility.

Digestive and systemic diseases

SIBO is reported more frequently in selected patients with conditions such as:

• Crohn’s disease,
• coeliac disease,
• chronic pancreatitis or pancreatic insufficiency,
• liver cirrhosis,
• severe hypothyroidism,
• and some immune disorders.

An association does not prove that SIBO is causing all symptoms in these patients. The underlying disease and bacterial overgrowth may produce overlapping clinical effects.

Reduced gastric acidity

Very low stomach acid, whether caused by disease, surgery or medication, may increase susceptibility in some individuals. Nevertheless, acid-suppressing medication should be assessed according to its medical indication rather than automatically blamed for digestive symptoms.

SIBO and IBS: Similar Symptoms, Different Questions

SIBO and irritable bowel syndrome frequently overlap in research and clinical practice. People with IBS are more likely than healthy controls to have a positive breath test, but reported prevalence varies greatly according to the test substrate, diagnostic threshold and study population.

A systematic review found that estimates of SIBO prevalence in IBS changed substantially depending on whether lactulose or glucose breath testing was used. This demonstrates how strongly the diagnostic method can influence who is labelled as having SIBO.

The two conditions should not automatically be treated as synonyms.

A person with IBS may have SIBO, but a positive breath test does not prove that bacterial overgrowth is the only cause of the symptoms. Conversely, a person may have clinically important bacterial overgrowth without meeting the diagnostic criteria for IBS.

This is one reason why treatment decisions should not be based on a single test result in isolation.

SIBO, Methane and Intestinal Methanogen Overgrowth

Methane detected during breath testing requires special interpretation.

Methane is mainly produced by methanogens, which belong to the domain Archaea rather than Bacteria. Methanogens may be present in both the small and large intestine. For this reason, the preferred term is now intestinal methanogen overgrowth, or IMO, rather than methane-predominant SIBO.

Under the North American Consensus, a methane concentration of at least 10 parts per million at any point during breath testing is considered methane-positive. A rise is not required in the same way as for hydrogen because methane may already be elevated at baseline. (PubMed)

Methane production is associated with slower intestinal transit and constipation. A systematic review and meta-analysis found a significant association between methane detected on breath testing and constipation-related disorders. More recent clinical research also supports a relationship between IMO and prolonged colonic transit.

This distinction is clinically relevant because patients with hydrogen-predominant SIBO and patients with IMO may have different symptom patterns and may require different treatment strategies.

How Is SIBO Diagnosed?

There is no perfect diagnostic test. Each available method has important limitations.

1. Small-bowel aspiration and culture

During an upper endoscopy, fluid can be collected from the duodenum or jejunum and cultured for microorganisms. A bacterial concentration of at least (10^3) colony-forming units per millilitre is commonly used in current clinical definitions, although higher thresholds have been used historically.

Aspiration has several theoretical advantages: it samples the small intestine directly and can identify some of the organisms present.

However, it is invasive, expensive and technically demanding. Samples may be contaminated by microorganisms from the mouth or upper digestive tract. Only a limited section of the intestine is sampled, so overgrowth farther downstream may be missed. Many intestinal organisms are also difficult to grow using standard culture methods.

Consequently, aspiration is often described as a reference method rather than an unquestionable gold standard.

2. Hydrogen and methane breath testing

Breath testing is the most widely used non-invasive approach.

The patient drinks a solution containing glucose or lactulose. Breath samples are then collected at regular intervals. Human cells do not produce hydrogen or methane; these gases originate primarily from microbial metabolism. After entering the bloodstream, they are transported to the lungs and exhaled.

According to the North American Consensus, a rise in hydrogen of at least 20 parts per million above baseline within 90 minutes is considered a positive result for SIBO. Methane of at least 10 parts per million at any time is considered methane-positive.

Glucose breath test

Glucose is rapidly absorbed in the proximal small intestine. This may reduce false-positive results caused by fermentation in the colon.

Its main disadvantage is that it may be absorbed before reaching bacterial overgrowth located in the more distal small intestine, potentially producing a false-negative result.

Lactulose breath test

Lactulose is not absorbed and travels through the entire small intestine before reaching the colon. It may therefore detect more distal fermentation.

The major problem is that lactulose inevitably reaches colonic bacteria. In people with rapid intestinal transit, an early rise in hydrogen may reflect fermentation in the colon rather than true bacterial overgrowth in the small intestine.

European and North American guidelines recognise the usefulness of breath testing while also highlighting substantial uncertainty concerning preparation, substrate choice, transit time and interpretation. (PubMed)

3. Clinical assessment and additional testing

A responsible assessment may also include:

• medical and surgical history,
• review of medications,
• evaluation of bowel habits,
• blood tests for anaemia and nutrient deficiencies,
• coeliac disease testing when appropriate,
• assessment for inflammatory or pancreatic disease,
• and imaging or endoscopy if structural disease is suspected.

The result of a breath test should be interpreted alongside the patient’s symptoms and pre-test probability—not as an isolated answer to every digestive complaint.

Why False Positives and False Negatives Occur

Breath testing is highly sensitive to preparation and gastrointestinal physiology.

Potential sources of error include:

• incomplete fasting,
• smoking or vigorous exercise during the test,
• recent antibiotic use,
• recent use of laxatives or bowel-cleansing preparations,
• variations in glucose or lactulose dose,
• slow or rapid intestinal transit,
• high gas concentrations before the test begins,
• and the presence of microorganisms that consume hydrogen to produce methane or other compounds.

Some people produce very little measurable hydrogen or methane despite experiencing microbial fermentation. Others may have rapid transit that causes colonic fermentation to occur before the conventional 90-minute cut-off.

For these reasons, the same person may receive different results depending on the laboratory protocol, substrate and interpretation criteria.

Treating SIBO: More Than Killing Bacteria

The objective of treatment is not simply to reduce a breath-test number. A comprehensive strategy should address three questions:

1. Is bacterial or methanogen overgrowth genuinely contributing to the symptoms?
2. What underlying factor allowed the overgrowth to develop?
3. Are there nutritional or structural consequences that need treatment?

Antibiotics

Antibiotics remain the principal medical therapy for clinically significant SIBO. Rifaximin is frequently used because it is poorly absorbed and acts mainly within the intestinal lumen.

A systematic review and meta-analysis found that rifaximin can improve breath-test results and symptoms in many patients. However, the authors also concluded that the overall quality of the available studies was generally poor and that better randomised trials were needed to determine the optimal regimen. (PubMed)

Other antibiotics may be considered according to the suspected organisms, methane status, previous treatment, allergies, local prescribing practices and underlying condition.

Antibiotic selection, dose and duration should be determined by a qualified clinician. Repeated or prolonged empirical treatment carries risks, including adverse effects, disruption of the wider microbiome and antimicrobial resistance. The AGA specifically notes that the evidence base guiding antibiotic strategies remains limited.

Treating the underlying cause

When possible, treatment should also address the factor responsible for microbial accumulation. This may involve:

• managing a motility disorder,
• correcting a structural abnormality,
• reviewing medications that slow intestinal transit,
• treating constipation,
• managing coeliac or inflammatory disease,
• correcting pancreatic insufficiency,
• or reassessing unnecessary long-term acid suppression.

Because digestive problems rarely involve only one mechanism, it may also be helpful to understand how intestinal permeability, accumulated digestive waste and microbiome balance can influence the wider gut environment.

Without addressing the underlying driver, the intestinal environment may continue to favour overgrowth.

Correcting nutritional deficiencies

People with significant diarrhoea, weight loss or malabsorption may require assessment of:

• vitamin B12,
• folate,
• iron,
• vitamin D,
• calcium,
• magnesium,
• and fat-soluble vitamins.

Supplementation should be guided by documented needs and the underlying condition.

Can Diet Cure SIBO?

Diet can influence symptoms, fermentation and microbial activity, but no standard diet has been conclusively shown to eradicate SIBO.

Low-FODMAP diets

FODMAPs are fermentable carbohydrates that can increase water retention and gas production in the intestine. A carefully designed low-FODMAP diet has strong evidence for reducing symptoms in selected people with IBS. (PubMed)

The evidence is less direct for SIBO. A low-FODMAP diet may reduce bloating, pain or diarrhoea by decreasing the amount of rapidly fermentable substrate available to microorganisms, but symptom improvement does not prove that bacterial overgrowth has been eliminated.

Strict long-term restriction may reduce dietary variety and intake of prebiotic fibres. The low-FODMAP approach is therefore normally used as a temporary elimination phase followed by systematic reintroduction and personalisation, ideally with guidance from a gastrointestinal dietitian.

Meal spacing

Because the migrating motor complex is most active during fasting periods, some clinicians recommend avoiding continuous grazing and allowing intervals between meals.

This approach has a plausible physiological rationale, but clinical evidence showing that meal spacing alone prevents or cures SIBO is limited. It should not become a rigid rule for people with diabetes, eating disorders, malnutrition, pregnancy or other conditions requiring individual meal planning.

Fibre

Fibre is not inherently harmful in SIBO. Different fibres have different physical and fermentative properties, and tolerance varies considerably.

Some people experience more bloating from rapidly fermented fibres, while others benefit from carefully selected soluble fibres that improve stool consistency and bowel regularity.

Once individual tolerance has been established, some people may prefer a ready-made blend of soluble and insoluble plant fibres with complementary botanical ingredients rather than combining several fibre sources themselves.

Unnecessarily eliminating all fibre may worsen constipation and reduce long-term dietary quality.

Elemental diets

An elemental diet contains nutrients in forms designed for rapid absorption, leaving relatively little material available for microbial fermentation.

A small study found that a 14-day elemental diet normalised abnormal lactulose breath tests in many participants with IBS. More recent research has continued to examine better-tolerated elemental formulations. Nevertheless, the evidence remains limited, and elemental diets can be restrictive, expensive and difficult to maintain.

They should be considered specialised medical interventions—not do-it-yourself cleansing programmes.

Do Probiotics Help or Harm?

There is no universal answer.

A 2017 meta-analysis suggested that probiotics might improve bacterial decontamination rates, reduce hydrogen production and relieve abdominal pain. However, the included studies used different strains, doses, diagnostic methods and patient populations.

More recent reviews have found inconsistent or statistically non-significant benefits, highlighting the low quality and heterogeneity of the evidence.

This means that “probiotics” should not be treated as one uniform intervention. A product containing one strain cannot be assumed to have the same effects as a multi-strain preparation or a different microbial species.

Some patients report improvement, while others experience increased gas, bloating or discomfort. Probiotics should therefore be evaluated according to the exact strain, clinical objective and individual response rather than being recommended—or rejected—as a category.

Why SIBO Often Comes Back

Recurrence is one of the central challenges in SIBO management.

In a study of 80 patients whose glucose breath tests became negative after rifaximin treatment, recurrent positivity was observed in:

• 12.6% after three months,
• 27.5% after six months,
• and 43.7% after nine months.

Older age, a history of appendectomy and chronic proton pump inhibitor use were associated with a greater likelihood of recurrence in this study. The return of a positive test was also accompanied by the return of gastrointestinal symptoms. (PubMed)

These figures come from one relatively small study and should not be interpreted as universal recurrence rates. They nevertheless illustrate an important principle: antibiotics may temporarily reduce microbial numbers without correcting the physiological conditions that allowed overgrowth to develop.

Long-term success may therefore depend on restoring motility, treating constipation, correcting structural problems, improving nutritional status and managing the underlying disease.

Five Common SIBO Myths

Myth 1: SIBO means the intestine contains only “bad” bacteria

The problem is not necessarily that every organism is harmful. Microorganisms that are harmless or beneficial in one intestinal location may interfere with digestion when present in excessive numbers elsewhere.

Myth 2: Bloating after meals proves that someone has SIBO

Bloating is common and has many possible causes. SIBO is only one consideration, particularly when there are relevant risk factors.

Myth 3: A positive breath test explains every symptom

A breath test may support a diagnosis, but it does not establish that SIBO is the sole cause of fatigue, skin symptoms, food intolerance, cognitive complaints or other nonspecific problems.

Myth 4: Carbohydrates must be avoided permanently

Temporary reduction of selected fermentable carbohydrates may reduce symptoms, but permanent severe carbohydrate restriction is not a proven cure and may unnecessarily reduce dietary quality.

Myth 5: One course of antibiotics permanently solves the problem

Some patients improve after one treatment, but recurrence is common when the underlying cause remains present.

When Medical Evaluation Is Especially Important

Professional evaluation is particularly important when digestive symptoms are accompanied by:

• unintentional weight loss,
• gastrointestinal bleeding or black stools,
• persistent vomiting,
• fever,
• severe or progressively worsening pain,
• iron-deficiency anaemia,
• vitamin B12 deficiency,
• persistent nocturnal diarrhoea,
• significant dehydration,
• a family history of gastrointestinal cancer,
• or the onset of new symptoms later in life.

These features may indicate a condition that requires investigation beyond SIBO testing.

The Most Rational Approach to Suspected SIBO

A practical evidence-based approach can be summarised as follows:

Step 1: Establish clinical probability

Consider the symptoms, previous surgery, motility problems, medications and underlying diseases. Testing every person with occasional bloating is unlikely to produce reliable answers.

Step 2: Choose and interpret testing carefully

Use a standardised glucose or lactulose breath-test protocol when appropriate. Interpret hydrogen and methane separately and recognise the possibility of IMO.

Step 3: Exclude important alternative diagnoses

Depending on the presentation, this may include coeliac disease, inflammatory bowel disease, pancreatic insufficiency, constipation, food malabsorption or structural disease.

Step 4: Treat the overgrowth when clinically justified

Antibiotics or other specialised interventions should be selected according to the individual clinical situation.

Step 5: Identify the reason it developed

Look for impaired motility, altered anatomy, medication effects, constipation or another underlying disease.

Step 6: Rebuild dietary tolerance

Use dietary restriction strategically and temporarily rather than eliminating large food groups indefinitely.

After symptoms have stabilised, the longer-term objective may include restoring dietary variety and, when well tolerated, introducing gentle fibre-based support for regular bowel movements and everyday digestive maintenance.

Step 7: Monitor the clinical response

The goal is meaningful improvement in symptoms, function and nutritional status—not simply a lower gas concentration on a laboratory report.

Conclusion: Location Is Part of Microbial Balance

SIBO demonstrates that the relationship between humans and microorganisms depends on context.

A bacterium does not need to be inherently dangerous to cause problems. When microorganisms become too numerous, metabolically overactive or established in an intestinal region designed primarily for digestion and absorption, they can interfere with normal physiology.

Yet SIBO should not become a universal explanation for every digestive symptom. Its definition remains imperfect, breath tests have limitations, dietary evidence is often extrapolated from IBS, and recurrence is common.

The most effective approach is therefore not simply to “kill bacteria.” It is to understand why the small intestine lost control of its microbial environment, correct reversible causes, treat clinically significant overgrowth, protect nutritional status and restore a sustainable relationship between diet, motility and the intestinal microbiome.

Frequently Asked Questions

Is SIBO contagious?

No. SIBO is generally caused by internal changes in intestinal anatomy, motility or digestive defences. It is not considered an infection that is normally transmitted from one person to another.

Can SIBO cause constipation?

Yes, but constipation is more strongly associated with intestinal methanogen overgrowth than with hydrogen-predominant bacterial overgrowth.

Can SIBO cause vitamin B12 deficiency?

It can, particularly in severe or prolonged cases involving malabsorption. Many patients with SIBO do not develop B12 deficiency, so laboratory testing should be based on clinical circumstances.

Can someone have SIBO without severe symptoms?

Possibly. The intensity of symptoms does not always correspond to the degree of gas production or microbial overgrowth. However, a positive test without compatible symptoms or risk factors should be interpreted cautiously.

Should everyone with SIBO follow a low-FODMAP diet?

No. A low-FODMAP diet may help selected patients control symptoms, but it is not a universal treatment and should not normally remain highly restrictive indefinitely.

Can SIBO be treated naturally?

Dietary changes and selected supportive strategies may reduce symptoms, but evidence for herbal products, probiotics and other alternative treatments is inconsistent. “Natural” does not automatically mean safe, effective or free from interactions. Clinically significant SIBO should be assessed with qualified medical guidance.

Bibliography

1. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology. 2020;115(2):165–178.
2. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020;159(4):1526–1532.
3. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology. 2017;112(5):775–784.
4. Hammer HF, Fox MR, Keller J, et al. European Guideline on Indications, Performance and Clinical Impact of Hydrogen and Methane Breath Tests. United European Gastroenterology Journal. 2022;10(1):15–40.
5. Saad RJ, Chey WD. Breath Testing for Small Intestinal Bacterial Overgrowth: Maximizing Test Accuracy. Clinical Gastroenterology and Hepatology. 2014;12(12):1964–1972.
6. Shah A, Talley NJ, Jones M, et al. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. American Journal of Gastroenterology. 2020;115(2):190–201.
7. Gatta L, Scarpignato C. Systematic Review with Meta-Analysis: Rifaximin Is Effective and Safe for the Treatment of Small Intestine Bacterial Overgrowth. Alimentary Pharmacology & Therapeutics. 2017;45(5):604–616.
8. Lauritano EC, Gabrielli M, Scarpellini E, et al. Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy. American Journal of Gastroenterology. 2008;103(8):2031–2035.
9. Kunkel D, Basseri RJ, Makhani MD, et al. Methane on Breath Testing Is Associated with Constipation: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. 2011;56(6):1612–1618.
10. Deloose E, Janssen P, Depoortere I, Tack J. The Migrating Motor Complex: Control Mechanisms and Its Role in Health and Disease. Nature Reviews Gastroenterology & Hepatology. 2012;9(5):271–285.
11. Su T, Lai S, Lee A, He X, Chen S. Meta-Analysis: Proton Pump Inhibitors Moderately Increase the Risk of Small Intestinal Bacterial Overgrowth. Journal of Gastroenterology. 2018;53(1):27–36.
12. Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review. Journal of Clinical Gastroenterology. 2017;51(4):300–311.
13. Niño SF, et al. Efficacy of Probiotics in the Treatment of Small Intestinal Bacterial Overgrowth. 2024.
14. Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test. Digestive Diseases and Sciences. 2004;49(1):73–77.
15. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology. 2014;146(1):67–75.e5.

This article is intended for educational purposes and does not replace individual medical diagnosis or treatment. Persistent or severe gastrointestinal symptoms should be evaluated by a qualified healthcare professional.